Welcome to our dedicated page for DURECT SEC filings (Ticker: DRRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Finding the trial data that could shift DURECT’s valuation shouldn’t feel like combing through a lab notebook. Biotech SEC filings are dense—hundreds of pages of clinical results, licensing clauses, and risk factors. DURECT Corporation’s 10-K alone details epigenetic therapy science, cash burn projections, and FDA designations that move the stock.
Stock Titan turns that complexity into clarity. Our AI delivers DURECT SEC filings explained simply—from the DURECT annual report 10-K simplified to every DURECT quarterly earnings report 10-Q filing. Need real-time alerts? We stream DURECT Form 4 insider transactions real-time so you can spot confidence buys or option exercises before the market reacts. Each document arrives with an AI-powered summary, key-metric extractions, and plain-language answers to questions like “What does the latest 8-K say about the AHFIRM trial?”
Here’s what you can unlock:
- Pipeline progress and cash-runway analysis inside 10-Qs—perfect for DURECT earnings report filing analysis
- DURECT insider trading Form 4 transactions mapped against clinical milestones to monitor sentiment
- Instant explanations of any DURECT 8-K material events explained—from FDA feedback to licensing deals
- Compensation metrics in the DURECT proxy statement executive compensation section, tied to trial success hurdles
Whether you’re understanding DURECT SEC documents with AI for the first time or scanning DURECT executive stock transactions Form 4 before earnings, Stock Titan provides complete coverage and professional insight—no PDF diving required.
James E. Brown, who is listed as President & CEO and a director of DURECT Corp (DRRX), reported a transaction dated 09/11/2025 involving the disposition of a stock option covering 103,077 shares with a $1.30 exercise/conversion price.
The filing explains this activity occurred in connection with a Merger Agreement and a related tender offer by Bausch Health Americas, Inc. Options with exercise prices below the cash consideration were accelerated and, if exercised before the merger became effective, the resulting shares were treated the same as other shares in the tender offer. Options with exercise prices equal to or above the cash consideration that remained unexercised at the effective time were canceled and former holders are eligible for cash retention bonuses tied to net sales milestones under a board-approved retention plan.
Insider grant and purchase reported: Director Gail M. Farfel reported a transaction in DURECT CORP (DRRX) showing acquisition of both common stock and a stock option on 09/10/2025. The filing shows 5,500 shares of common stock acquired at $1.22 per share, bringing Ms. Farfel's direct holdings to 15,500 shares. The filing also discloses a stock option granted on the same date with a $1.22 exercise price covering 5,500 underlying shares; the option becomes fully exercisable one day before the first anniversary of grant and expires on 09/25/2034. The Form 4 is signed 09/11/2025 and identifies Ms. Farfel as a director filing individually.
James E. Brown, President & CEO and a director of DURECT Corporation (DRRX), reported two option grants on 09/09/2025 and 09/10/2025. Each grant is reported with transaction code M (award of options) for 131,923 and 130,000 stock options respectively, both with an exercise price of $1.30 and an expiration date of 10/14/2034. The filings show post-transaction direct beneficial ownership of 415,335 shares after the first grant and 545,335 shares after the second grant, plus 8,000 shares held indirectly by the Brown Family Trust dated 5/10/2006. The options vest in installments of one-sixteenth every three months following the grant, subject to continuous service.
Judith J. Robertson, a director of DURECT Corp (DRRX), received an equity award consisting of a stock option covering 5,500 shares exercisable at $1.22 per share. The option grant date and associated transaction is reported as 09/10/2025. The option vests 100% on the day before the first anniversary of the grant, conditioned on continued service through the vesting date. After the reported grant and related exercise rights, Ms. Robertson beneficially owns 41,113 shares of common stock and holds options covering an additional 5,500 shares that expire on 09/25/2034. The disclosure is a Form 4 reporting a director-level equity award and resulting beneficial ownership.
Peter S. Garcia, a director of DURECT Corporation (DRRX), received an option grant on 09/09/2025 covering 5,500 shares with an exercise price of $1.22. The Form 4 shows the option is a stock option exercisable for 5,500 shares of common stock and that the reporting person owned 12,500 shares of common stock following the transaction. The disclosure states the option vests 100% on the day before the first anniversary of the grant date, subject to continued service.
Gail J. Maderis, a director of DURECT Corporation (DRRX), reported option and stock activity on 09/09/2025. The filing shows the grant of a stock option to purchase 5,500 shares at an exercise price of $1.22, with the option exercisable after vesting and an expiration date of 09/25/2034. The option vests 100% on the day before the first anniversary of the grant, subject to continued service. The report also shows acquisition of 5,500 shares of common stock (direct) and indirect beneficial ownership of 20,000 shares held by the Gail J. Maderis Revocable Trust dated 04-08-2013, for reported holdings of 5,500 direct and 20,000 indirect shares following the transaction.
Durect Corporation filed an S-8 registration statement listing multiple prior S-8 registrations and the number of common shares registered under various employee plans across years. The filing documents repeated registrations of shares for the 2000 Stock Plan and the Employee Stock Purchase Plan, including large blocks such as
Durect Corporation (DRRX) filed an S-8 post-effective amendment registering shares for employee benefit plans. The filing lists multiple prior S-8 registration statements and the specific share amounts registered under various plans, including recent entries of 40,000 shares under the Employee Stock Purchase Plan and 2,000,000 shares under the 2000 Stock Plan (each number shown after the 1-for-10 reverse stock split). The document also notes the 1-for-10 reverse stock split effected on December 5, 2022, and is signed by CFO Timothy M. Papp.
Durect Corporation filed an S-8 prospectus in connection with multiple prior S-8 registrations and to register 2,000,000 shares of Common Stock under its 2000 Stock Plan (amounts shown are after the 1-for-10 reverse stock split effected on